3.49 (-%)
As of Dec 10, 2024
Source:
Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel synthetic lethality-based cancer therapeutics that target DNA damage response pathways. Our approach is built upon a platform of integrated discovery technologies to enrich our pipeline with novel targets in synthetic lethality and cancer treatment.
Country | United States |
Headquarters | doylestown, pennsylvania |
Phone Number | 267-370-5219 |
Industry | manufacturing |
CEO | Oren Gilad |
Website | aprea.com |